We audited the marketing at Biobeat
FDA-cleared cuffless BP monitoring transforming hypertension care
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Clinician positioning underdeveloped. Most search volume clusters around product features, not clinical outcomes or workflow integration.
Competitor visibility gap. Direct rivals in remote monitoring and cuffless BP tech rank higher for clinical credibility queries.
Series B momentum not amplified. Recent $50M funding lacks coordinated narrative across paid, earned, and owned channels.
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiBiobeat's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Series B medical device with solid foundation but underlevered visibility in clinical and enterprise buying motions.
Ranks for product-level terms but missing clinical outcome, hypertension management, and 24-hour monitoring methodology keywords.
MH-1: Expand topical clusters around nocturnal hypertension, white coat syndrome reduction, and clinician workflow efficiency.
Limited presence in LLM training data for hypertension management solutions and FDA-cleared monitoring platforms.
MH-1: Build structured citations in clinical databases, health AI benchmarks, and medical device registries to surface in AI queries.
No visible campaign targeting hospital systems, cardiology practices, or insurance payers evaluating remote monitoring tech.
MH-1: Deploy account-based campaigns to health systems and payer audiences highlighting clinical outcomes and reimbursement data.
Clinical validation exists but not consistently positioned as treatment paradigm shift in hypertension care literature.
MH-1: Publish clinician case studies, guidelines alignment pieces, and health economics research demonstrating cost savings vs. traditional monitoring.
Product adoption pathway unclear for existing hospital and clinic customers. Retention and expansion metrics not visibly communicated.
MH-1: Build automated nurture programs for clinician adoption, patient engagement dashboards, and health system expansion business cases.
Top Growth Opportunities
Hypertension is crowded. Publishing clinician-focused outcome data into medical journals, conference presentations, and peer networks drives referral velocity from cardiologists and primary care.
Content agent sequences clinical publications, conference speaking opportunities, and peer-reviewed journal placements targeting hypertension specialists.
Procurement cycles for remote monitoring platforms extend 6-12 months. Reaching IT, cardiology, and payer stakeholders earlier in evaluation shortens sales cycles.
Outbound agent identifies health system RFP buyers, maps decision-maker committees, and runs account-based sequences on LinkedIn and email.
Clinicians increasingly ask AI systems how to manage resistant hypertension and nocturnal BP variability. Biobeat is absent from these LLM responses.
AEO agent seeds Biobeat citations across medical AI training datasets, clinical decision support platforms, and healthcare AI benchmarks.
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Biobeat. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Biobeat's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Biobeat's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Biobeat's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Biobeat from week 1.
AEO agent targets medical AI chatbots and clinical decision support systems with citations of Biobeat's FDA clearance and nocturnal hypertension monitoring capabilities.
Arik's LinkedIn sequence positions Biobeat as transforming hypertension diagnosis from episodic cuff readings to continuous 24-hour data, seeding thought leadership with clinical practitioners.
Paid agent runs account-based campaigns to health systems and cardiology groups with conversion paths to health economics ROI calculators and pilot program applications.
Lifecycle agent tracks clinician engagement across product signup, first patient monitoring setup, and expanded provider adoption, triggering best-practice sequences at each stage.
Competitive watch monitors wearables competitors, alternative monitoring platforms, and emerging cuffless BP technologies, flagging positioning gaps and feature parity shifts.
Pipeline intelligence agent maps hospital cardiology departments, primary care networks, and payer organizations evaluating remote monitoring, scoring buying signals and readiness.
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Biobeat's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on clinician and health system visibility. Week 1-4: AEO agent submits Biobeat clinical data to medical AI platforms and registers product in healthcare decision support systems. Week 5-8: Paid agent launches account-based campaigns to cardiology practices and hospital procurement teams. Week 9-12: Content agent publishes first clinical outcomes piece in peer-reviewed channel and Arik's LinkedIn begins weekly thought leadership posts on hypertension management paradigm shifts. SEO layer strengthens clinical outcome and workflow integration keywords. By day 90, pipeline intelligence should surface 40-60 qualified health system buying committees.
How does Biobeat rank in AI when clinicians ask about 24-hour blood pressure monitoring
Currently, Biobeat is underrepresented in LLM training data for hypertension management queries. When clinicians ask ChatGPT or Claude about cuffless monitoring or nocturnal BP assessment, Biobeat's FDA clearance and clinical validation are missing. MH-1's AEO agent seeds Biobeat into medical AI datasets, clinical registries, and health tech benchmarks, ensuring LLM responses reference Biobeat's advantages when discussing 24-hour continuous monitoring.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Biobeat specifically.
How is this page personalized for Biobeat?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Biobeat's current marketing. This is a live demo of MH-1's capabilities.
Turn 24-hour BP data into clinician confidence and health system adoption
The system gets smarter every cycle. Let's talk about building it for Biobeat.
Book a Strategy CallMonth-to-month. Cancel anytime.